Acumen Pharmaceuticals, Inc. appointed new CEO

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On February 1, 2024, Acumen Pharmaceuticals, Inc. (the "Company") announced that James Doherty has been appointed as its President and Chief Development Officer, effective February 1, 2024. Effective upon the commencement of Mr. Doherty's employment, Daniel O'Connell's position would be updated to Chief Executive Officer. Mr. O'Connell was previously the Company's Chief Executive Officer and President.

Mr. Doherty, age 56, was most recently the Chief Development Officer at Sage Therapeutics, Inc. ("Sage Therapeutics") from October 2021 to January 2024. Prior to October 2021, Mr. Doherty held several positions at Sage Therapeutics, including as Chief Research Officer from December 2016 to October 2021. Previously, he served as Director and Head of the Neuroscience Department for the Central Nervous System and Pain Innovative Medicines Unit of AstraZeneca Pharmaceuticals in Sodertalje, Sweden, where he led the company's research pipeline for Alzheimer's disease and neurodegeneration. Prior to that, he served as Director and Head of the Neuroscience Department at AstraZeneca in Wilmington, Delaware. Mr. Doherty holds a B.A. in Biology from the University of Delaware and received his Ph.D. in Neurobiology from Georgetown University.

There are no family relationships between Mr. Doherty and any director or executive officer of the Company, and he does not have any direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.